Skip to main content
JCR Pharmaceuticals Co.,Ltd. logo

JCR Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 4552 ISIN · JP3701000006 LEI · 353800IMIU9CQ1DGOS14 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2024-02-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4552

About JCR Pharmaceuticals Co.,Ltd.

https://www.jcrpharm.co.jp/en/site/en/

JCR Pharmaceuticals is a global specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of treatments for rare and genetic diseases. The company's portfolio includes therapies for conditions such as growth disorders, Mucopolysaccharidosis II (Hunter syndrome), and Fabry disease. A primary area of innovation involves developing treatments for central nervous system (CNS) disorders by utilizing proprietary technology to deliver biotherapeutics across the blood-brain barrier. JCR also develops and sells regenerative medicine products, aiming to address complex healthcare challenges and provide new treatment options for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
四半期報告書－第49期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the third quarter of the 49th fiscal year (period ending December 31, 2023). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management analysis. This fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-14 Japanese
訂正確認書
Audit Report / Information Classification · 95% confidence The document text contains the header "訂正有価証券報告書（通常方式）" which translates to "Amended Securities Report (Normal Method)". It references the Financial Instruments and Exchange Act ("金融商品取引法") and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). A Securities Report (Yuka Shoken Hokokusho) in the US context is equivalent to a 10-K or 10-Q. Since this is an amendment/correction to a report covering a full fiscal year (implied by the context of a major filing being corrected, though the period cited is 2022/04/01 to 2023/03/31, which is a full year), and it is a formal regulatory filing confirming the accuracy of the underlying report, it is most closely related to the Annual Report (10-K) structure, or potentially a general regulatory filing (RNS). However, the core document type being addressed is the Securities Report, which is the Japanese equivalent of the 10-K. Given the specific nature of confirming the accuracy of a full-year report, 10-K is the most appropriate classification among the provided options, even though the document itself is a confirmation/amendment filing. FY 2023
2024-01-19 Japanese
訂正有価証券報告書－第48期(2022/04/01－2023/03/31)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (訂正有価証券報告書) for an Annual Securities Report (有価証券報告書) filed under the Financial Instruments and Exchange Act of Japan. It includes metadata and XBRL tags related to the company's fiscal year (第48期, 2022-04-01 to 2023-03-31). In the Japanese regulatory context, the '有価証券報告書' is the equivalent of the US 10-K. Since this is a formal filing of the annual report (or a correction thereof), it falls under the 10-K category. FY 2023
2024-01-19 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text is titled '第２四半期報告書' (Second Quarter Report) and contains a confirmation statement ('確認書') regarding the appropriateness of the contents of the company's Q2 report for the 49th period (July 1, 2023, to September 30, 2023). This structure, focusing on a specific interim financial period and containing confirmation/attestation rather than the full financial statements or management discussion, strongly aligns with the definition of an Interim/Quarterly Report (IR). Although it is a confirmation document related to the report, the core subject matter is the comprehensive quarterly filing itself, making 'IR' a more accurate classification than a simple 'RPA' or 'RNS' which are usually announcements about the report's release. The presence of specific fiscal periods (Q2, July 1 to Sept 30) confirms it relates to a formal periodic report.
2023-11-14 Japanese
四半期報告書－第49期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the second quarter of the 49th fiscal year (April 1, 2023, to September 30, 2023). It contains detailed financial statements, management analysis (MDA), and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). Q2 2024
2023-11-14 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act Article 24-4-8. It serves as an officer certification confirming the accuracy of the quarterly report, rather than being the quarterly report itself. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS). Q1 2023
2023-08-10 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.